Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter ...

JPMorgan keeps a Neutral rating on Genmab (GMAB) with a DKK 1,700 price target after the company announced that Johnson & Johnson (JNJ) has ...

Genmab A/S said that Johnson & Johnson has decided not to exercise its option to obtain a worldwide license for the ...

Genmab shares fell on Monday after the company said it would end the development of blood-cancer treatment HexaBody-CD38 because Johnson & Johnson won't exercise its option to license it.

PerfectServe®, a leading provider of cloud-based clinical collaboration and provider scheduling solutions, today announced the launch of its fifth annual Nurses of Note awards program. The program has ...

Genmab has stopped clinical development of a blood cancer treatment after Johnson & Johnson decided it won't exercise its option to license it.

The Jalapeño Popper Grilled Cheese is available for just $10.99 CAD (or $9.49 USD) at participating Chopped Leaf locations ...

Quvia, the AI-powered QoE platform formerly known as Neuron, today announced Q, a suite of embedded AI tools designed to maximize productivity and efficiency for connectivity, digital operations, and ...

Genmab A/S (Nasdaq: GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize ...

EDT Genmab (GMAB) falls 7% to $22.44 after J&J declines option on HexaBody-CD38Discover the Best Stocks and Maximize Your Portfolio: ...

The decision comes after Genmab provided J&J with data from a clinical proof-of-concept study, which included a head-to-head comparison with DARZALEX FASPRO® (daratumumab and hyaluronidase fihj) in ...